Atsushi Hiraoka

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma

M. Kudo, R. Kelley, D. Pinato, 2023, JAMA oncology.

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

R. Finn, A. Singal, M. Premkumar, 2023, EClinicalMedicine.

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Y. Hiasa, A. Morishita, J. Tani, 2023, Cancers.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.

Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings

M. Kudo, Y. Hiasa, A. Morishita, 2023, Oncology.

ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.

K. Matsuura, A. Morishita, J. Tani, 2024, Journal of gastroenterology.